Biocon Biologics acquires Viatris' biosimilar business for $3.34 billion

BBL said the cash payment of $2 billion to be funded by $800 million raised through equity infusion in BBL and the remainder to be funded by debt, additional equity or a combination.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dMD0eyV
via IFTTT